European Congress of Rheumatology

Health literacy was categorized as problematic in 36.2% of patients and insufficient in 15.1%.

At 8 months follow-up, 86.0% of patients with rheumatoid arthritis were in remission and 94.2% exhibited low disease activity.

Phase 3 data presented at EULAR found the biosimilar CT-P47 is similar to its reference product, tocilizumab, regarding efficacy, safety, and immunogenicity.

Within the reactive care gout conversations, “pain” and “swelling” were significantly more likely to be mentioned when compared with proactive care conversations.

Between 2000 and 2019, age-standardized incidence rates of autoimmune diseases increased by 4%.

Adverse events were significantly more frequently reported by pregnant patients when compared with non-pregnant patients. However, no differences were observed when comparing pregnant patients with autoimmune disease and healthy controls.

The results of the study provide a proof of concept for upadacitinib treatment in patients with systemic lupus erythematosus.

Patients treated with upadacitinib maintained greater improvements in SLE disease activity, lupus flares, and time to first flare when compared with the placebo cohort.

Data indicate dazodalibep has the potential to address unmet therapeutic needs for patients with Sjögren’s syndrome.